Selenium Intake and Glycemic Control in Young Adults With Normal-Weight Obesity Syndrome

Acsa de Castro Santos1†, Anna Flavia Ferreira Passos1†, Luciana Carla Holzbach1,2 and Cristiane Cominetti1*

1 Nutritional Genomics Research Group. Graduate Program in Nutrition and Health, School of Nutrition, Federal University of Goias, Goiania, Brazil, 2 Nutrition Undergraduate Course, Federal University of Tocantins, Palmas, Brazil

Numerous endogenous functions related to antioxidant processes, reproduction, and thyroid metabolism, as well as actions related to glycemic control, have been attributed to selenium. This study aimed to evaluate whether dietary selenium consumption is associated with variables of glycemic control in a sample of young Brazilian adults with Normal-Weight Obesity (NWO) syndrome. This was a cross-sectional study that evaluated 270 individuals with adequate body weight and excess body fat, who had their body composition assessed by dual-energy X-ray absorptiometry. Socioeconomic, health, and lifestyle questionnaires and three 24-h food records were applied. Glycemic control markers were also evaluated. The prevalence of inadequate selenium intake was analyzed by the Estimated Average Requirement (EAR) cut-point method. The prevalence of disturbances in glycemic control markers according to selenium consumption was compared by either the chi-square or the Fisher’s exact test, with individuals classified according to the EAR values for selenium. The associations were evaluated by multiple linear regressions, using the backward strategy. The mean ± standard deviation (SD) age was 23.7 ± 3.3 years, and the mean ± SD daily selenium intake was 59.2 ± 26.4 µg. The overall prevalence of inadequate selenium intake was 59.2%. Individuals with selenium intakes below the EAR (≤45 µg/day) showed higher concentrations of glycated hemoglobin (HbA1c) (P = 0.002) and a higher prevalence of disturbances in HbA1c than those with selenium intakes above the EAR (>45 µg/day) (P = 0.001). Dietary selenium intake was directly associated with female sex (β = 19.95, 95% CI 5.00 to 34.89; P = 0.001) and weight (β = 6.69, 95% CI 0.56 to 12.81; P = 0.010), and inversely associated with the percentage of total body fat (β = −0.80, 95% CI −1.56 to −0.04; P = 0.010) and HbA1c (β = −7.41, 95% CI −13.06 to −1.75; P = 0.010). Considering the noticeable young age of the individuals evaluated and the high frequency of disturbances in HbA1c concentrations in those with selenium consumption below the recommendation, it is suggested that adequate dietary intake or supplementation of this micronutrient should be guaranteed to prevent future possible complications associated with glycemic control disturbances.

Keywords: adults, adiposity, lifestyle, food consumption, glycated hemoglobin A
INTRODUCTION

Selenium is a trace element that fulfills key roles related to human body homeostasis, thyroid gland function, and optimal functioning of the immune system (1, 2). Most of these actions are due to its participation as a component or cofactor of antioxidant enzymes, such as glutathione peroxidase and thioredoxin reductase, in addition to deiodinases (1). Inadequate serum selenium concentrations are associated with disorders of the thyroid gland (2), cancer (3), metabolic syndrome, cardiovascular disease, diabetes (4, 5), and obesity—albeit in a contradictory way (6–8).

Obesity in the classic sense, defined by the Body Mass Index (BMI), has been extensively studied in several aspects, including selenium metabolism. However, more recently, emphasis has been placed on the substantial role of excess body fat regardless of BMI classification. In 2006, the Normal-Weight Obesity (NWO) syndrome, a metabolic condition of excess body fat in individuals with normal BMI, was defined (9). It is known that individuals with NWO have a particular profile concerning the development of some harmful conditions, with emphasis on cardiometabolic risk factors, such as insulin resistance (IR) and dyslipidemias. These markers of cardiometabolic health are among the important aspects that should be evaluated and monitored in individuals with NWO because this condition seems to favor metabolic disorders in an intermediary way between individuals with normal BMI and body composition and those with obesity. Therefore, the role of dietary selenium intake in glycemic control in these individuals should also be investigated.

Although the most selenium-rich food is widely available in Brazil, there are few studies on the consumption of selenium in the Brazilian population and none in individuals with NWO. Analysis of the dietary intake of 34,003 Brazilians older than 10 years revealed a mean selenium intake of 107.6 µg/day, with no difference between income classes or urban and rural areas. Higher selenium intakes were found in women and residents of the northern region of Brazil. Among the elderly, mean selenium intake was lower than that in other age groups but still above the RDA (10), in contrast to the results of a study on elderly residents in the Rio Grande do Sul state, southern Brazil, which found an inadequate intake rate of 98% (11).

In general, studies investigating the relationship between selenium and glycemic control show contradictory results regarding glycemia and the prevalence of type 2 diabetes mellitus (DM2) but converge concerning serum insulin and the Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) index and suggest that its action occurs through some mechanisms, including regulation of insulin signaling and glycolysis, pyruvate, and chromium metabolism (7, 12–15), as well as promoting changes in the expression of genes related to insulin and adiponectin receptors (INSR and ADIPOR1) and others that encode pyruvate metabolism enzymes (LDH, PDHA, PDHB) (16, 17).

In addition, it is believed that selenium could play a protective role against disorders of glucose metabolism by regulating oxidative stress and mimicking insulin action (18, 19). However, important results of a study with data from samples of American individuals (14) showed that selenium is associated with a higher risk of DM2. Therefore, it is currently believed that high serum selenium concentrations increase the risk of insulin resistance or DM2 (20). One explanation is that selenoprotein glutathione peroxidase 1 (GPX-1) is overexpressed under high selenium concentrations (21). Overexpression of GPX-1 has been associated with insulin resistance in rats (22) and decreased expression of PKM, the gene encoding the glycolytic enzyme pyruvate kinase (23).

In a recent meta-analysis with studies including individuals from Europe and Asia with diseases such as DM2, gestational diabetes, polycystic ovary syndrome, heart disease, obesity, and others, selenium supplementation was shown to decrease the Homeostasis Model Assessment of Beta-Cell Function (HOMA-beta) and increase the Quantitative Insulin Sensitivity Check Index (QUICKI); however, it had no effect on blood glucose, HOMA-IR, glycated hemoglobin (HbA1c), and adiponectin concentrations (8). In addition, after 16 years of monitoring more than 10,000 women in Italy, it was observed that those who developed diabetes, among other factors, had higher dietary selenium intake (60.9 vs. 56.8 µg/day) (24).

Considering that the association of dietary selenium intake with markers of glycemic control has produced variable results depending on the study population and that a similar investigation has not yet been carried out in adults with NWO, this study aimed to evaluate whether dietary selenium consumption is associated with glycemic control variables in a sample of young adults with NWO. The hypothesis is that selenium consumption is associated with serum concentrations of glucose; insulin; HbA1c; and the HOMA-IR, HOMA-beta, and QUICKI indexes in these individuals.

MATERIALS AND METHODS

Design and Population

This study was carried out using two databases, applying the same inclusion and exclusion criteria. Both databases came from observational, analytical, and cross-sectional studies, collected from an academic community in Goiânia, Goiás, Brazil. The recruitment of volunteers was carried out through folders, social networks, and emails sent to students, employees, and professors at the Federal University of Goias (UFG), Brazil (Figure 1). The studies were approved by the UFG Research Ethics Committees (protocols n°: 2,772,022, Jul 16, 2018 and n°: 865.062, Nov 10, 2014). All volunteers received information and clarification about all procedures and signed a consent form.

Both men and women aged between 20 and 59 years, with normal BMI (between 18.50 and 24.99 kg/m²) (25) and high body fat percentages (9, 25) were included. One hundred thirteen individuals were recruited in the first study and 157 in the second study, totaling 270 volunteers (Figure 1). The statistical power was estimated using R software, with an effect size of 0.21, a type I error probability of 0.05, and a sample size of 270 observations. The estimated power was 0.858.
Study Population and Measurements
The first data collection was performed from May to September 2015, and the second one, from January to June 2019. Data collection took place in two meetings after participant recruitment. During the first appointment, individuals received all information about the research, and the informed consent form was presented. Individuals who met the inclusion criteria and agreed to participate answered the socioeconomic, demographic, lifestyle, and health questionnaires and were referred for anthropometric assessment, body composition, and food consumption analysis. The second appointment was previously scheduled, and the individuals were instructed to fast for 12 h to collect blood samples for biochemical tests.

All researchers on the team in both studies were trained and underwent standardization regarding the nutritional care protocol. In addition to this training, the researchers received training to measure anthropometric measures, according to the technique of anthropometry standardization recommended by Habicht (26).

Socioeconomic, Demographic, Lifestyle, and Blood Pressure Data
The application of a questionnaire referring to socioeconomic, demographic, and lifestyle data took place in an average of 30–40 min. During this stage, blood pressure was measured at three non-consecutive moments, and the mean values of systolic and diastolic pressures were used in the analyses (27).

Anthropometric Evaluation
Body mass was measured on a digital platform scale (Filizola Shop, São Paulo, Brazil), with a maximum load of 150 kg and an accuracy of 0.1 kg. Height was determined using a stadiometer (Seca Deutschland, Hamburg, Germany) with a maximum reach of 220 cm and a precision of 0.1 cm, according to the procedures described by Lohman et al. (28).

Body Composition Analysis
Individuals dressed in light clothing and without accessories were subjected to DEXA examination, using a Lunar DPX NT model DEXA scanner (General Eletric Medical Systems Lunar®, Madison, USA).

Determination of Glycemic Profile Markers
Blood was collected by a specialized technician, with disposable materials, in a strictly sanitized environment, from the median cubital vein for determination of the glycemic profile (fasting blood glucose, fasting insulin, and HbA₁c). The colorimetric enzymatic method was used to determine the fasting blood glucose values, and the reference value for disturbances was ≥100 mg/dL (29). The electrochemiluminescence method was applied to determine the serum insulin concentration. The immunoturbidimetric inhibition method was used to determine the concentration of HbA₁c, and the percentage was
compare means. A comparison of the disturbances in glycemic control markers between individuals consuming selenium at levels below and above the EAR was performed using either the chi-square or Fisher's exact test, according to the number of individuals who presented disturbances. Associations between variables were assessed by multiple linear regression models, using the backward strategy. The variables that could associate with glycemic response and were added to the model included sex, weight, height, BMI, body fat percentage, and HbA1c, age, systolic and diastolic blood pressure, waist circumference, android and gynoid fat, the android/gynoid ratio, fasting blood glucose, insulinemia, and the HOMA-IR, HOMA-beta, and QUICKI indexes. Although selenium intake was the main focus of the analysis, other dietary variables that also could interfere with glycemic response were added to the model, including carbohydrate, total fat; saturated, monounsaturated and polyunsaturated fatty acids; and protein intakes.

A value of $P < 0.05$ was considered statistically significant, and all analyses were performed in R software version 4.0.3 (35).

**RESULTS**

The total sample consisted of 270 adults (113 individuals from the study conducted in 2015 and 157 from the one conducted in 2019) (Figure 1), with NWO (adequate BMI and a high percentage of body fat). The mean ± SD age was 23.7 ± 3.3 years, and 70.4% of the participants were women.

For selenium, individuals showed a mean intake of 59.2 ± 26.4 µg/day. The overall prevalence of inadequate intake was 59.2% (54.7% for men and 63.7% for women). To analyze glycemic control marker disturbances, individuals were separated into two groups according to selenium consumption: (1) below the EAR (≤45 µg/day)—91 individuals (33.7%); and (2) above the EAR (>45 µg/day)—179 individuals (66.3%) (Table 1). When comparing the total sample according to sex, 30.5% ($n = 58$) of women and 41.2% ($n = 33$) of men showed selenium consumption below the EAR ($P = 0.089$).

There were no differences in weight, BMI, waist circumference, body fat percentage (% BF), android fat, and gynoid fat between the two groups (below and above the EAR). Individuals in the group below the EAR showed higher values of the ratio between android/gynoid body fat compared to those in the group above the EAR (Table 1).

Individuals in the group with selenium intake above the EAR had lower concentrations of HbA1c than those in the group with intake below the EAR ($P = 0.002$) (Table 2). In addition, a higher prevalence of disturbances in HbA1c concentrations was found in the group with selenium consumption below the EAR compared with the one with intake above EAR ($P = 0.001$) (Table 3). No differences were found in the other biomarkers of glycemic control between the two groups (Table 3).

Three individuals were excluded from the regression analysis due to missing data (n = 267). After all candidate variables were added into the multiple regression model using the backward strategy, the final model with the lowest Akaike criterion presented the variables sex, weight, height, BMI, body fat percentage, and HbA1c. Sex, weight, body fat percentage,
TABLE 1 | Descriptive data of individuals with Normal-Weight Obesity Syndrome, according to the classification of dietary selenium intake.

|                      | Below EAR (n = 91–33.7%) | Above EAR (n = 179–66.3%) | Total (n = 270–100.0%) | P-value |
|----------------------|---------------------------|---------------------------|------------------------|---------|
| Sex                  |                           |                           |                        | 0.089   |
| Male                 | 33 (36.3)                 | 47 (26.3)                 | 80 (29.6)              |         |
| Female               | 58 (63.7)                 | 132 (73.7)                | 190 (70.4)             |         |
| Age (years)          | 22.4 (21.1–26.3)          | 23.0 (21.2–25.0)          | 23.0 (21.2–25.0)       | 0.879   |
| Selenium intake      | 33.4 ± 9.3                | 72.4 ± 22.2               | 59.2 ± 26.4            | 0.001   |
| MSBP (mmHg)          | 108.4 ± 11.3              | 107.0 ± 10.8              | 107.5 ± 11.0           | 0.343   |
| MDBP (mmHg)          | 65.5 (60.5–72.0)          | 65.0 (60.0–72.0)          | 65.0 (60.0–72.0)       | 0.606   |
| Weight (kg)          | 61.2 (56.5–66.8)          | 60.6 (55.2–67.0)          | 61.0 (55.4–66.8)       | 0.649   |
| Height (m)           | 1.7 (1.6–1.8)             | 1.7 (1.6–1.7)             | 1.7 (1.6–1.7)          | 0.481   |
| BMI (kg/m²)          | 22.5 ± 1.6                | 21.8 (20.7–23.2)          | 22.0 (21.0–23.4)       | 0.476   |
| MET (min/week)       | 400.0 (120.0–898.0)       | 297.0 (140.0–565.0)       | 330.0 (132.8–726.0)    | 0.062   |
| %BF                  | 34.7 (26.5–40.3)          | 35.2 (30.4–38.8)          | 35.0 (29.4–39.2)       | 0.672   |
| %AF                  | 37.5 (31.6–43.1)          | 35.2 (30.2–41.8)          | 35.8 (30.8–42.4)       | 0.308   |
| %GF                  | 46.2 (34.4–50.7)          | 47.1 (41.0–50.3)          | 46.7 (38.3–50.4)       | 0.475   |
| A/G                  | 0.9 ± 0.1                 | 0.8 ± 0.1                 | 0.8 ± 0.1              | 0.005   |

Data are absolute numbers (percentages), mean ± standard deviation or median (interquartile range). MSBP, mean systolic blood pressure (mmHg); MDBP, mean diastolic blood pressure (mmHg); BMI, body mass index; MET, metabolic equivalent of task; %BF, body fat percentage; %AF, android body fat percentage; %GF, gynoid body fat percentage; A/G, ratio between %AF/%GF. Student’s t-test or Mann-Whitney test.

TABLE 2 | Biochemical characterization of individuals with Normal-Weight Obesity Syndrome, according to dietary selenium intake.

|                      | Below EAR (n = 91–33.7%) | Above EAR (n = 179–66.3%) | Total (n = 270–100.0%) | P-value |
|----------------------|---------------------------|---------------------------|------------------------|---------|
| Blood glucose (mg/dL)| 85.5 ± 7.3                | 85.2 ± 7.5                | 85.3 ± 7.4             | 0.800   |
| Insulin (µU/mL)      | 7.2 (5.9–9.9)             | 7.2 (5.0–9.4)             | 7.2 (5.1–9.8)          | 0.443   |
| HOMA-IR              | 1.6 (1.1–2.2)             | 1.5 (1.0–2.1)             | 1.5 (1.1–2.1)          | 0.384   |
| HOMA-Beta            | 122.9 (83.8–164.5)        | 118.3 (88.3–171.6)        | 122.0 (86.5–169.0)     | 0.881   |
| HbA1c (%)            | 5.1 (4.7–5.6)             | 4.8 (4.6–5.1)             | 4.9 (4.6–5.3)          | 0.002   |
| QUICKI index         | 0.36 (0.34–0.38)          | 0.36 (0.34–0.38)          | 0.36 (0.34–0.38)       | 0.387   |

Data are mean ± standard deviation or median (interquartile range). HOMA-IR, homeostasis model assessment of insulin resistance; HOMA Beta, homeostatic model assessment of beta-cell function; HbA1c, glycated hemoglobin. Student’s t-test or Mann-Whitney test.

TABLE 3 | Disturbances in biomarkers of glycemic control of individuals with Normal-Weight Obesity Syndrome, according to dietary selenium intake.

|                      | Below EAR (n = 91) | Above EAR (n = 179) | Total (n = 270) | P-value |
|----------------------|-------------------|--------------------|-----------------|---------|
| Blood glucose        | 2 (2.2)           | 9 (5.0)            | 11 (4.1)        | 0.344   |
| HOMA-IR              | 6 (6.6)           | 18 (10.1)          | 24 (8.9)        | 0.345   |
| HOMA-beta            | 7 (7.7)           | 20 (11.2)          | 27 (10.0)       | 0.366   |
| HbA1c (%)            | 20 (22.0)         | 15 (8.4)           | 35 (11.5)       | 0.001   |
| Quicki index         | 8 (8.8)           | 19 (10.6)          | 27 (10.0)       | 0.637   |

Data are absolute numbers (percentage). HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-beta, homeostatic model assessment of beta-cell function; HbA1c, glycated hemoglobin. Fisher’s exact test or Chi-square test.

and HbA1c were the variables most strongly associated with dietary selenium intake. The female sex was directly associated with a higher consumption of selenium (β = 19.95, 95% CI 5.00 to 34.89; P = 0.001), and a positive association was also observed for selenium consumption and weight (β = 6.69, 95% CI 0.56 to 12.81; P = 0.010). However, negative associations of body fat percentage and HbA1c with selenium consumption were observed (β = −0.80, 95% CI −1.56 to −0.04; P = 0.010, and β = −7.41, 95% CI −13.06 to −1.75; P = 0.010, respectively). The final regression model is shown in Table 4. The variables that sequentially left the model during the backward procedure to derive the final regression model were age; systolic blood pressure; diastolic blood pressure; waist circumference; android fat; gynoid fat; the android/gynoid ratio; fasting blood glucose; insulinemia; and the HOMA-IR, HOMA-beta, and QUICKI indexes. It is important to highlight that the regression model was also tested only for females, considering the highest percentage of women in the sample; however, as the results were not different from those observed in the analysis of both sexes combined (data not shown), it was decided to present the results of the total sample. In addition, adding macronutrients, saturated, monounsaturated, and polyunsaturated fatty acids to the regression model did not influence the results.
not change the association between dietary selenium intake and HbA$_{1c}$.

**DISCUSSION**

The assessment of risk markers for metabolic diseases in individuals with NWO is important to reduce the medium and long-term risks of cardiovascular diseases and DM2. In a quick search of the scientific literature, it is possible to identify many studies that investigate the relationship between selenium supplementation and glycemic control markers; however, few report this association for food consumption, and none has been carried out with individuals with NWO.

Our results show that mean dietary selenium consumption was above that recommended by the DRIs (59.2 ± 26.4 µg/day); however, approximately one third of participants did not reach the expected minimum values. We also observed that dietary selenium intake was inversely associated with serum concentrations of HbA$_{1c}$ and body fat percentage. Individuals with intake above the EAR for selenium had lower concentrations of HbA$_{1c}$, which may suggest better glycemic control. Although HbA$_{1c}$ should not be used alone for DM2 diagnosis or glycemic profile monitoring, it is extremely relevant in clinical practice, as it allows for screening of mean blood glucose in the last 90 days (36). The association with body fat percentage draws attention to the need of monitoring this parameter in addition to the BMI.

Studies about the action of selenium on glycemic control have produced divergent results. A recent meta-analysis of randomized clinical trials (RCTs), including 1,441 individuals with ages ranging from 10 to 85 years, verified that selenium supplementation reduced insulin secretion as assessed by the HOMA-beta index and increased the QUICKI index; however, significant results were not observed for disturbances in HOMA-IR and HbA$_{1c}$ concentrations (8). On the other hand, in a study with 2,420 non-diabetic Canadians (mean age of 42 years), dietary selenium intake was positively associated with glycemic control, so that insulin resistance, measured by HOMA-IR and HOMA-beta, decreased with increasing selenium consumption among women but not among men ($P < 0.001$); lower daily selenium consumption was observed among those with the highest HOMA-IR indexes ($P < 0.001$) and a negative correlation between selenium and insulin resistance was observed up to a consumption limit of 1.6 µg/kg/day (37). Although this study shows relevant data, the mean dietary consumption of selenium (109.22 ± 1.18 µg/day) was 1.84 times higher than that observed in our study, which makes comparisons of results difficult.

Two RCTs on selenium supplementation carried out in Danish elderly and Polish adults reinforce our main result that higher intakes of selenium are associated with lower concentrations of HbA$_{1c}$, even within different populations and with different doses of selenium (16, 38). By contrast, some studies have failed to demonstrate a decrease in HbA$_{1c}$ concentrations (12, 39) or found high serum selenium concentrations associated with increased concentrations of glucose and HbA$_{1c}$, as in 41,474 American adults with a mean dietary selenium intake of 98.0 ± 55.0 µg/day (40) and in 8,824 Chinese with a mean consumption of 52.4 µg/day (41).

Some mechanisms to justify the controversial action of selenium in relation to the processes associated with glucose metabolism are speculated. An *in vivo* study with diabetic mice showed that the use of sodium selenate increased the expression of peroxisome proliferator-activated receptor gamma (PPAR-γ), which acts on insulin resistance and increases lipid metabolism (42). The selenium compounds of the oxidation state +IV inhibited the activity of protein tyrosine phosphatases (PTP) (42), responsible for dephosphorylating the insulin receptor, attenuating its action (43). In this context, selenium as sodium selenite would antagonize and compromise glycemic control.

Robertson and Harmon (44) and Campbell et al. (45) suggest that selenium could provide protection against DM2 due to its association with oxidative stress control by increasing the activity of GPx in pancreatic beta cells and decreasing the damage caused by reactive oxygen species (ROS). This was verified in a mouse beta-cell line (Min6) in which beta-cell sensitivity increased.
in response to sodium selenate, expressed via increased GPx activity (5-fold), and a notable increase in the activity of insulin promoter factor 1 (Ipf1). A response to sodium selenite was also observed via increased mRNA levels of Ipf1 and Ins. The increased antioxidant activity of GPx culminates in beneficial effects on the level of pancreatic beta-cell mass and insulin synthesis; however, long-term increased insulin production and secretion can result in chronic hyperinsulinemia (46).

In our study, in addition to the results observed in relation to HbA1c concentrations, positive associations were found between dietary selenium consumption with female sex and weight, and an inverse association between selenium intake and body fat percentage was observed. The Canadian CODING study with 3,054 participants (adults from the province of Newfoundland, in eastern Canada, mean age of 42 years), observed a mean dietary selenium consumption of 108.10 µg/day, and decreasing consumption in µg/kg/day along the BMI ranges. The authors found a significant and dose-dependent association between tertiles of selenium consumption and weight, BMI, waist circumference, total body fat percentage, and gynoid and android fat percentages and demonstrated that dietary selenium can account, regardless of other factors, for 9–27% of the variation in body fat percentage (47).

Thereafter, a study published by the same group of CODING (n = 2,420), showed divergent results regarding the type of association between dietary selenium consumption and body weight but also observed an inverse association with body fat percentage, BMI, and body water (37). A similar result was also found in a study with a representative national sample of Chinese individuals, in which the body fat percentages were also lower in individuals consuming selenium in the highest quintiles compared with those with intake in the lowest quintiles (41).

Possible explanations for the role of selenium in adipogenesis are also related to PPAR-γ, which is responsible for adipocyte differentiation and distribution of adipose tissue, and is thus related to increased tissue insulin sensitivity and weight control. In animals receiving sodium selenate, hepatic PPAR-γ expression was 2.5 times higher than in those with selenium deficiency or treated with sodium selenite (42). On the other hand, a recent study with rat and human cell cultures of pre-adipocytes showed inhibition of adipogenesis due to a decrease in the expression of PPAR-γ and fatty acid synthase mRNAs, while there was an increase in growth factor-β (48). The mechanisms involved in the association of selenium with adiposity are not yet fully elucidated, but there is evidence suggesting that serum selenium concentrations are negatively associated with adiposity, especially visceral fat. However, this information needs to be carefully considered because it involves numerous other processes and not only dietary selenium intake as a modifier of serum concentration (49).

Among the limitations of our study, the cross-sectional design can be considered, as it does not allow us to make inferences about cause and effect between dietary selenium consumption and the other markers. However, it suggests that there may be interactions between the consumption of this nutrient and glycemic control markers and, for this reason, may guide future investigations on dietary consumption and the effect of selenium on biochemical and metabolic pathways and the expression of genes related to variation in HbA1c concentrations. We were not able to measure blood selenium levels, which can also be considered a limitation. On the other hand, this is the first study to assess associations between dietary selenium intake and markers of glycemic control in individuals with NWO.

In conclusion, dietary consumption of selenium above the minimum values recommended for groups by the dietary guidelines was associated with lower serum HbA1c concentrations, a long-term marker of disturbances in blood glucose, and body fat percentage. Considering that the individuals evaluated in our study had NWO, and the disturbances in HbA1c found in the group consuming selenium below the EAR, we can observe that despite their noticeably young age, these individuals showed cardiometabolic markers that are more commonly seen in older people. Therefore, further studies with individuals with NWO are strongly recommended, as one of the basic principles of nutrition is to reduce or mitigate the risk of non-communicable chronic diseases throughout life.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, upon a reasonable request.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by UFG Research Ethics Committee. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AS and AP: acquisition, interpretation, and analysis of data. LH: data interpretation and writing the manuscript. CC: conceptualization, experimental design, obtaining resources, interpretation of data, and writing the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors would like to thank all the members of the research team who assisted in all stages of data collection of both studies, and each volunteer who participated in the study.
REFERENCES

1. Mehdì Y, Hornick JL, Isted L, Dufrasne I. Selenium in the environment, metabolism and involvement in body functions. Molecules. (2013) 18:3292–11. doi: 10.3390/molecules18 033292

2. Stuss M, Michalska-Kasczak M, Sewerynek E. The role of selenium in thyroid gland pathophysiology. Endokrynol Pol. (2017) 68:440–65. doi: 10.5063/EP.2017.0051

3. Vinceti M, Filippini T, Cilloni S, Crespi CM. The epidemiology of selenium and human cancer. Adv Cancer Res. (2017) 136:1–48. doi: 10.1016/bs.acr.2017.07.001

4. Méplén, Hughes DJ. The role of selenium in health and disease: emerging and recurring trends. Nutrients. (2020) 12:120–3. doi: 10.3390/n12041049

5. Schomburg L, Otho-Melander M, Struck J, Bergmann A, Melander O. Selenoprotein-P deficiency predicts cardiovascular disease and death. Nutrients. (2019) 11:1852. doi: 10.3390/n11081852

6. Kohler LN, Foote J, Kelley CP, Florea A, Shelly C, Chow HHS, et al. Selenium and type 2 diabetes: systematic review. Nutrients. (2018) 10:1–13. doi: 10.3390/n10011924

7. Kohler LN, Florea A, Kelley CP, Chow S, Hsu P, Batai K, et al. Higher plasma selenium concentrations are associated with increased odds of prevalent type 2 diabetes. J Nutr. (2018) 148:1333–40. doi: 10.1093/jn/nxy099

8. Mahdavi Gorabi A, Hasani M, Djalalinia S, Zarei M, Ejtahed H, Abdar ME, et al. Effect of selenium supplementation on glycemic indices: a meta-analysis of randomized controlled trials. J Diabetes Metab Disord. (2019) 18:349–62. doi: 10.4020/s02019-001494-w

9. De Lorenzo A, Martinoli R, Vaia F, Di Renzo L. Normal weight obese (NWO) women: an evaluation of a candidate new syndrome. Nutr Metab Cardiovasc Dis. (2006) 16:513–23. doi: 10.1146/numed.2005.10.010

10. Tureck C, Correa VG, Peralta R, Koehlein E. Intakes of antioxidant vitamins and minerals in the Brazilian diet. Nutr Clin Diet Hop. (2013) 33:30–8. doi: 10.12877/333Braziliandiet

11. Pannizer FB, Dorneles MM. Evaluation of antioxidant minerals intake in elderly. Rev Bras Geriatr Gerontol. (2006) 14:49– 58. doi: 10.1590/S1519-9823201000100006

12. Bahmani F, Kia M, Soleimani A, Asemi Z, Esmaillzadeh A. Effect of selenium supplementation on glycemic control and lipid profiles in patients with diabetic nephropathy. Biol Trace Elem Res. (2016) 172:282–9. doi: 10.1007/s12011-015-0600-4

13. Farrokhian A, Bahmani F, Taghizadeh M, Mirhashemi SM, Aarabi M, Raygan F, et al. Selenium supplementation affects insulin resistance and serum hs-CRP levels in patients with type 2 diabetes and coronary heart disease. Horm Metab Res. (2016) 48:263–8. doi: 10.1055/s-0035-1569276

14. Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium concentrations and diabetes in U.S. adults. Environ Health Perspect. (2009) 117:2003–4. doi: 10.1289/ehp.0900704

15. Hansen AF, Simic A, Asvold BO, Romundstad PR, Midthjell K, Syversen T, et al. Trace elements in early phase type 2 diabetes mellitus—a population-based study. The HUNT study in Norway. J Trace Elem Med Biol. (2017) 40:46–53. doi: 10.1016/j.jtemb.2016.12.008

16. Jablonska E, Reszka E, Gromadzinska J, Wieczorek E, Krol MB, Raimondi RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. (1985) 28:412–9. doi: 10.1003/ajcn/65.4.1220S

17. Basiotis P, Welsh SO, Cronin FJ, L Kelsey J, Mertz W. Number of days of food intake records required to estimate individual and group nutrient intakes with defined confidence. J Nutr. (1987) 117:1638–41. doi: 10.1093/jn/117.9.1638

18. Mosfiegh AJ, Rhodes DG, Baer DJ, Murayi T, Clemens JC, Rumphler W V., et al. The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intake. Am J Clin Nutr. (2008) 88:324–32. doi: 10.1093/ajcn/88.2.324

19. Raper N, Perloff B, Ingwersen L, Steinfeldt L, Anand J. An overview of USDA dietary intake data system. J Food Compos Anal. (2004) 17:545– 55. doi: 10.1016/j.jfca.2004.02.013

20. Willett WC, Howe R, Kushi LH. Adjustmentfor total energy intake in epidemiologic studies. Am J Clin Nutr. (1997) 65:1220S–85. doi: 10.1093/ajcn/65.4.1220S

21. R Core Team. R Version 4.0.3, 2020 Bunny-Wunnies Freak Out Copyright

22. American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. (2013) 36(Suppl. 1):S1–116. doi: 10.2337/dci13-0101

23. Wang Y, Lin M, Gao X, Pedram P, Du J, Vikram C, et al. High dietary selenium intake is associated with less insulin resistance in the Newfoundland population. PLoS ONE. (2017) 12:1–15. doi: 10.1371/journal.pone.0174149

24. Stranges S, Rayman MP, Winther KH, Guallar E, Cold S, Pastor-Barrious R. Effect of selenium supplementation on changes in HbA1c: Results from a multiple-dose, randomized controlled trial. Diabetes Obes Metab. (2019) 21:541–9. doi: 10.1111/dom.13549

25. Bahmani F, Kia M, Soleimani A, Mohammadi AA, Asemi Z. The effects of selenium supplementation on biomarkers of inflammation and oxidative stress in patients with diabetic nephropathy: a randomised double-blind, placebo-controlled trial. Br J Nutr. (2016) 116:1222–8. doi: 10.1017/s0007114516003251

26. Lin J, Shen T. Association of dietary and serum selenium concentrations with glucose level and risk of diabetes mellitus: a cross sectional study of national health and nutrition examination survey, 1999–2006. J Trace Elem Med Biol. (2021) 63:126600. doi: 10.1016/j.jtemb.2020.126600
41. Siddiqi SM, Sun C, Wu X, Shah I, Mehmood A. The correlation between dietary selenium intake and type 2 diabetes: a cross-sectional population-based study on North Chinese adults. *Biomed Res Int.* (2020) 2020:8058463. doi: 10.1155/2020/8058463

42. Mueller AS, Pallauf J. Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. *J Nutr Biochem.* (2006) 17:548–60. doi: 10.1016/j.jnutbio.2005.10.006

43. Carvalheira JB, Zecchin HG, Saad MJA. Insulin signaling pathways. *Arq Bras Endocrinol Metab.* (2002) 46:419–25. doi: 10.1590/S0004-27302002000400013

44. Robertson RP, Harmon JS. Pancreatic islet β-cell and oxidative stress: the importance of glutathione peroxidase. *FEBS Lett.* (2007) 581:3743–8. doi: 10.1016/j.febslet.2007.03.087

45. Campbell SC, Aldibbiat A, Marriott CE, Landy C, Ali T, Ferris WF, et al. Selenium stimulates pancreatic beta-cell gene expression and enhances islet function. *FEBS Lett.* (2008) 582:2333–7. doi: 10.1016/j.febslet.2008.05.038

46. Wang XD, Vatamaniuk MZ, Wang SK. Molecular mechanisms for hyperinsulinaemia induced by overproduction of selenium-dependent glutathione peroxidase-1 in mice. *Diabetologia.* (2008) 51:1515–24. doi: 10.1007/s00125-008-1055-3

47. Wang Y, Gao X, Pedram P, Shahidi M, Du J, Yi Y, et al. Significant beneficial association of high dietary selenium intake with reduced body fat in the CODING study. *Nutrients.* (2016) 8:1–15. doi: 10.3390/nu8010024

48. Kim CY, Kim G, Wiacek JL, Chen C, Kim K. Biochemical and Biophysical Research Communications Selenate inhibits adipogenesis through induction of transforming growth factor-β1 (TGF-β1) signaling. *Biochem Biophys Res Commun.* (2012) 426:551–7. doi: 10.1016/j.bbrc.2012.08.125

49. Zhong Q, Lin R, Nong Q. Adiposity and serum selenium in U.S. adults. *Nutrients.* (2018) 10:727. doi: 10.3390/nu10060727

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Santos, Passos, Holzbach and Cominetti. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.